Dr. Yan Huang 黄岩
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer and nasopharyngeal carcinoma.
Dr. Yan Huang is a Chief Physician with a doctoral degree and master’s supervisor at Sun Yat-sen University Cancer Center. Clinical expertise includes chemotherapy, targeted therapy, immunotherapy, and new drug clinical research for lung cancer and nasopharyngeal carcinoma.
Professional roles
- Member, Tumor Drug Clinical Research Professional Committee, China Anti-Cancer Association
- Standing Committee Member, CSCO Supportive Care and Rehabilitation Expert Committee
- Standing Committee Member, Chemotherapy Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, Precision Medicine Professional Committee, Guangdong Clinical Medical Association
Name order: in Chinese the family name comes first (Huang Yan). Papers usually list the name as Yan Huang or Huang Y.
Selected publications
255 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2026 (senior author): Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PubMed 42497381
- J Immunother Cancer, 2026 (senior author): DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. PubMed 42601174
- Lung Cancer, 2026 (first author): Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study. PubMed 41887130
- Eur J Cardiothorac Surg, 2026 (first author): Differential Survival Outcomes of Satisfactory Tumour Response (ypStage I) Following Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy of Oesophageal Squamous Cell Cancer. PubMed 41851983
- Theranostics, 2026 (first author): The B-cell-autoantibody axis in lung cancer immunity. PubMed 41799207
- JAMA Oncol, 2026 (first author): Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. PubMed 41609753
- Qual Life Res, 2025 (first author): Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. PubMed 41313568
- Cancer Immunol Immunother, 2025 (first author): Correction: Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study. PubMed 41160160
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion